Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab by Lauren Klute, Matthew Solverson, Christopher M. Bingcang, Jayme R. Dowdall

“…We present a case of hemoptysis in a young female patient undergoing treatment for metastatic breast cancer with trastuzumab emtansine. Though previously associated with diffuse spontaneous hemorrhage of the gingiva, there have not been reports of laryngeal hemorrhage with trastuzumab emtansine treatment. …”
Get full text

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

“…Eligible patients had HER2-positive, metastatic breast cancer previously treated with taxane, trastuzumab, and pertuzumab, and were T-DM1-naïve. …”
Get full text

Trastuzumab Resistance: Role for Notch Signaling by Kinnari Mehta, Clodia Osipo

“…However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. Numerous mechanisms that include overexpression of alternate receptor tyrosine kinases and/or loss of critical tumor suppressors have been proposed in the last several years to elucidate trastuzumab resistance. …”
Get full text

Maternal Mortality: 10 Year Experience of a Tertiary Center in Turkey by Erdem Fadiloglu, Canan Unal, Atakan Tanacan, Serpil Ocal, Banu Kilicaslan, Seda Banu Akinci, Arzu Topeli, M. Sinan Beksac

“…Maternal mortality causes were cardiopulmonary failure secondary to veno-occlusive disease, septic shock secondary to osteosarcoma, pulmonary thromboembolism secondary to metastatic breast cancer, septic shock secondary to cholecystitis, and postpartum hemorrhage secondary to Niemann–Pick disease. …”
Get full text

Changes in Cytokines of the Bone Microenvironment during Breast Cancer Metastasis by Donna M. Sosnoski, Venkatesh Krishnan, William J. Kraemer, Courtenay Dunn-Lewis, Andrea M. Mastro

“…In this study, we examined levels of MCP-1, IL-6, KC, MIP-2, VEGF, MIG, and eotaxin in femurs of athymic nude mice inoculated via intracardiac injection with MDA-MB-231GFP human metastatic breast cancer cells, MDA-MB-231BRMS1GFP, a metastasis suppressed variant, or PBS. …”
Get full text

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data by Gabriel Tremblay, Patrick Haines, Andrew Briggs

“…The techniques are then applied to a metastatic breast cancer (MBC) example. **Methods:** A criterion-based guide was devised to allow the accurate extrapolation and justification of survival estimates in a MBC study comparing eribulin (Halaven) monotherapy with treatment of their (patient’s) physician’s choice (TPC). …”
Get full text

Understanding metastasis mixed-treatment responses through genomic analyses by Susana Garcia-Recio, Paola Zagami, Brooke M. Felsheim, Amy Wheless, Kerry Thomas, Renato Trimarchi, Lisa A. Carey, Charles M. Perou

“…Abstract Early-stage and metastatic breast cancers (MBC) can exhibit genomic heterogeneity, even within the same individual. …”
Get full text

Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective by Alberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi, Ninh M La-Beck

“…While PLD has gained a strong foothold in relapsed ovarian cancer and metastatic breast cancer, it has not been extensively tested in primary (neoadjuvant) and adjuvant therapy and has not fulfilled the expectations from the results in animal models efficacy-wise. …”
Get full text

Herbal Extract SH003 Suppresses Tumor Growth and Metastasis of MDA-MB-231 Breast Cancer Cells by Inhibiting STAT3-IL-6 Signaling by Youn Kyung Choi, Sung-Gook Cho, Sang-Mi Woo, Yee Jin Yun, Sunju Park, Yong Cheol Shin, Seong-Gyu Ko

“…Therefore, we conclude that SH003 suppresses highly metastatic breast cancer growth and metastasis by inhibiting STAT3-IL-6 signaling path.…”
Get full text

Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage by Paul Gonzales, Seth Klusewitz, Johanna Marowske, John Gancayco, Michael B. Osswald, Robert Setlik

“…Our case demonstrates recurrent episodes of gastrointestinal bleeding in a 60-year-old woman being treated with Everolimus for progressive metastatic breast cancer. On endoscopy, bleeding was secondary to erosive gastritis. …”
Get full text

Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors by Zhengyan Kan, Ji Wen, Vinicius Bonato, Jennifer Webster, Wenjing Yang, Vladimir Ivanov, Kimberly Hyunjung Kim, Whijae Roh, Chaoting Liu, Xinmeng Jasmine Mu, Jennifer Lapira-Miller, Jon Oyer, Todd VanArsdale, Paul A. Rejto, Jadwiga Bienkowska

“…Abstract To better understand drug resistance mechanisms to CDK4/6 inhibitors and inform precision medicine, we analyze real-world multi-omics data from 400 HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapies, including 200 pre-treatment and 227 post-progression samples. …”
Get full text

Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study by Xiaofeng Xie MD, Mingrui Ma MD, Xue Bai BS, Jing Hu MD, Haijie Zheng MD, Xiongqi Guo BS, Jiayi Huang MD, Xuelian Chen PhD, Liping Chen BS, Xiaofeng Lan BS, Lin Song BS, Caiwen Du PhD

“…Methods Data from patients newly diagnosed with metastatic breast cancer (MBC) between June 2017 and June 2022 were extracted from medical records at the authors’ hospital. …”
Get full text

Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer by Vittoria Marchio, Giuseppina Augimeri, Catia Morelli, Adele Vivacqua, Cinzia Giordano, Stefania Catalano, Diego Sisci, Ines Barone, Daniela Bonofiglio

“…However, triple-negative breast cancer (TNBC) and metastatic breast cancer disease are primarily treated with chemotherapy, which improves disease-free and overall survival, but does not offer a curative solution for these aggressive forms of breast cancer. …”
Get full text

Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone by Tiina E. Kähkönen, Mari I. Suominen, Jenni H. E. Mäki-Jouppila, Jussi M. Halleen, Azusa Tanaka, Michael Seiler, Jenni Bernoulli

“…This model can be used for evaluating the efficacy of combination treatments of IO therapies with immune-stimulatory compounds or therapeutic approaches on bone metastatic breast cancer.…”
Get full text

Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis by Rasanpreet Kaur, Saurabh Gupta, Sunanda Kulshrestha, Vishal Khandelwal, Swadha Pandey, Anil Kumar, Gaurav Sharma, Umesh Kumar, Deepak Parashar, Kaushik Das

“…The metabolome holds a future, and this review is an attempt to amalgamate the present relevant literature that might yield crucial insights for creating innovative therapeutic strategies aimed at addressing metastatic breast cancer.…”
Get full text

Spatial and temporal changes of breast-conserving surgery rates and its influential factors among Chinese patients with breast cancer from 2013 to 2019: a registry-based study by Pengpeng Ye, Yuan Yang, Wei Hu, Lingyan Dai, Erwei Song, Shunrong Li, Liling Zhu, Kai Chen, Yanjie Xu, Xiaoyu Wang, Jianli Zhao, Jianrong He, Queran Lin, Tongrui Shang, Xiujuan Gui, Ziliang Zhong, Qianru Chen, Qing Yan, Xiaoliang Huang, Zijian Liang

“…Patients with non-metastatic breast cancer, who underwent breast surgery between 2013 and 2019, were included.Main outcomes and measures We analysed the BCS rate in Guangdong Province between 2013 and 2019. …”
Get full text

Intensity-modulated radiation therapy for early-stage breast cancer: a systematic review and meta-analysis by Samir Abdallah Hanna, Bruna Salani Mota, Fabio Ynoe de Moraes, Gustavo Nader Marta, Heloísa de Andrade Carvalho, Rachel Riera

“…ABSTRACT BACKGROUND: Radiation therapy (RT) is a standard treatment for non-metastatic breast cancer and is associated with acute and late toxicities. …”
Get full text

Cytotoxic and cytostatic activity of five new imidazotetrazine derivatives on breast cancer cell cultures MDAMB231, BT474, and MCF-7 by Ahmed Hamid Al-Humairi, Svetlana E. Sitnikova, Valery V Novochadov

“…Introduction: The work presents the results of the study of new imidazotetrazine derivatives to establish the possibility of using them as anticancer agents, including for chemotherapy of metastatic breast cancer. The relevance of the work is due to the wide spread of oncological diseases and high cancer mortality, which dictates the need to constantly obtain cell lines and improve cultivation protocols for testing new antitumor drugs. …”
Get full text

A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer by Mehmet Zahid Kocak, Murat Araz, Siddika Findik, Aykut Demirkiran, Mustafa Korkmaz, Melek Karakurt Eryilmaz, Mehmet Artac

“…This is the first clinical study to determine the effect of CRELD2 on survival and as a prognostic marker in patients with triple metastatic breast cancer. These results need to be validated prospectively with a large sample size. …”
Get full text

Single-cell profiling transcriptomic reveals cellular heterogeneity and cellular crosstalk in breast cancer lymphatic node, bone, and brain metastases by Longyu Zhu, Miaomiao Liu, Yuguang Shang, Jingge Cheng, Hongye Zhao, Jun Zhang, Dongxing Shen

“…We identified seven cell clusters in primary and metastatic breast cancer (Lymphatic node, brain, and bone metastases) by analyzing single-cell transcriptomic profiles. …”
Get full text